Live Breaking News & Updates on Patients with active psoriatic arthritis

Stay updated with breaking news from Patients with active psoriatic arthritis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Philip J. Mease, MD: New Data on Guselkumab for Psoriatic Arthritis Patients

This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.
....

Spondyloarthritis-ps , Philipj-mease , University-of-washington-school-medicine , Swedish-medical-center , American-college-of-rheumatology , Drug-administration , Janssen-pharmaceuticals-inc , Corevitas-psoriatic-arthritis , Spondyloarthritis-registry , Janssen-pharmaceuticals , Washington-school

TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Italy , Horsham , Saskatchewan , Canada , Spring-house , Pennsylvania , United-states , Milan , Lombardia , Japan , Canadian , Scandj-rheumatol

Johnson & Johnson : TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment. | May 31, 2023 ....

Horsham , Saskatchewan , Canada , Pennsylvania , United-states , Milan , Lombardia , Italy , Japan , Spring-house , Canadian , Zismand-comorbidities

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with. ....

Canada , Washington , United-states , Japan , University-of-washington , Spring-house , British-columbia , Horsham , Saskatchewan , Seattle , Donvitot-creakyjoints , Terence-rooney

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology
ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ for the treatment …
– ABBVie (NYSE: ABBV) today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year efficacy and safety data for RINVOQ (upadacitinib ....

United-states , Canada , American , Canadian , Chiedzo-mpofu , Corevita-ps , Upadacitinib-pharmacokinetics , Global-medical-affairs , Abbvie-ltd , Linkedin , European-commission , Drug-administration